$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

$tnfa Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010384 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$0.00
YoY Change
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.057M	$1.338M	$6.215M
YoY Change	-29.16%	-26.44%	-71.03%
% of Gross Profit
Research & Development	$770.4K	$2.470M	$9.067M
YoY Change	-70.7%	88.88%	34.43%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$770.4K	$3.808M	$9.067M
YoY Change	-81.31%	1.96%	-68.53%
Operating Profit	-$2.590M	-$3.808M	-$15.28M
YoY Change	-37.16%	1.96%	-46.95%
Interest Expense	$1.199M	$62.52K	$80.99K
YoY Change	-26058.66%	-91.1%	1318.39%
% of Operating Profit
Other Income/Expense, Net	$1.079M		$85.43K
YoY Change	-599315.0%		-107.91%
Pretax Income	-$1.512M	-$3.746M	-$15.20M
YoY Change	-63.33%	15.61%	-49.15%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.512M	-$3.746M	-$15.20M
YoY Change	-63.33%	15.61%	-49.15%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04		-$0.39
Diluted Earnings Per Share	-$0.04	-$0.09	-$0.39
COMMON SHARES
Basic Shares Outstanding	39.47M shares	39.47M shares	38.83M shares
Diluted Shares Outstanding			1.294M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.55M	$4.836M	$4.836M
YoY Change	69.22%	-58.16%	-58.16%
Cash & Equivalents	$188.5K	$749.1K	$749.1K
Short-Term Investments	$15.36M	$4.087M	$4.087M
Other Short-Term Assets	$738.1K	$565.8K	$565.8K
YoY Change	-16.51%	-48.86%	-48.86%
Inventory
Prepaid Expenses	$738.1K	$565.8K
Receivables
Other Receivables
Total Short-Term Assets	$16.29M	$5.402M	$5.402M
YoY Change	61.7%	-57.35%	-57.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$123.8K	$139.7K	$139.7K
YoY Change	-6.73%	-6.27%	-6.27%
Goodwill	$10.50M	$10.50M
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments	$1.500M	$1.500M	$1.500M
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$12.12M	$12.14M	$12.14M
YoY Change	-0.07%	-0.08%	-0.08%
TOTAL ASSETS
Total Short-Term Assets	$16.29M	$5.402M	$5.402M
Total Long-Term Assets	$12.12M	$12.14M	$12.14M
Total Assets	$28.41M	$17.54M	$17.54M
YoY Change	27.95%	-29.31%	-29.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.369M	$2.673M	$2.357M
YoY Change	-31.41%	170.95%	171.64%
Accrued Expenses	$169.9K	$316.7K	$382.5K
YoY Change	-63.89%	165.86%	121.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.626M	$2.769M	$2.769M
YoY Change	-34.1%	166.28%	166.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.78M	$75.94K	$75.94K
YoY Change	11048.8%	-39.68%	-39.68%
Total Long-Term Liabilities	$12.78M	$75.94K	$75.94K
YoY Change	11048.8%	-39.68%	-39.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.626M	$2.769M	$2.769M
Total Long-Term Liabilities	$12.78M	$75.94K	$75.94K
Total Liabilities	$14.40M	$2.845M	$2.845M
YoY Change	457.92%	144.04%	144.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$95.43M	-$93.76M
YoY Change		19.34%
Common Stock	$108.4M	$108.3M
YoY Change		6.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.09M	$14.70M	$14.70M
YoY Change
Total Liabilities & Shareholders Equity	$28.41M	$17.54M	$17.54M
YoY Change	27.95%	-29.31%	-29.31%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.512M	-$3.746M	-$15.20M
YoY Change	-63.33%	15.61%	-49.15%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.972M	-$2.248M	-$12.27M
YoY Change	67.85%	-53.28%	-37.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$11.27M	$2.688M	$6.913M
YoY Change	-475.89%	-10.37%	-65.17%
Cash From Investing Activities	-$11.27M	$2.688M	$6.913M
YoY Change	-475.89%	-10.37%	-65.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.550M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$14.69M	0.000	$5.550M
YoY Change		-100.0%	7447.98%
NET CHANGE
Cash From Operating Activities	-$3.972M	-2.248M	-$12.27M
Cash From Investing Activities	-$11.27M	2.688M	$6.913M
Cash From Financing Activities	$14.69M	0.000	$5.550M
Net Change In Cash	-$560.5K	439.2K	$193.1K
YoY Change		-153.62%	-52.63%
FREE CASH FLOW
Cash From Operating Activities	-$3.972M	-$2.248M	-$12.27M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent		usd
CY2022Q4	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent		usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001321834
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2022	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022	us-gaap	Gross Profit GrossProfit		usd
CY2021	us-gaap	Gross Profit GrossProfit		usd
CY2022	MYMD	Accretion Of Debt Discount AccretionOfDebtDiscount		usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	MYMD	Stock Option Modification Expenses StockOptionModificationExpenses		usd
CY2022	MYMD	Gain On Debt Forgiveness GainOnDebtForgiveness		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	MYMD	Exercise Of Prepaid Equity Forward Contracts For Common Stock ExerciseOfPrepaidEquityForwardContractsForCommonStock		usd
CY2021	MYMD	Issuance Of Postmerger Common Shares At Exchange Ratio Per Premerger Common Share IssuanceOfPostmergerCommonSharesAtExchangeRatioPerPremergerCommonShare		usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2021	MYMD	Exercise Of Prepaid Equity Forward Contracts For Common Stock ExerciseOfPrepaidEquityForwardContractsForCommonStock		usd
CY2022	MYMD	Accrued Interestdividends AccruedInterestdividends		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022	MYMD	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt		usd
CY2022	MYMD	Stock Option Modification Expenses StockOptionModificationExpenses		usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2022	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets		usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	MYMD	Other Asset Investment OtherAssetInvestment		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Or Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36268
CY2022	dei	Entity Registrant Name EntityRegistrantName	MyMD Pharmaceuticals, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NJ
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2983783
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	855 N. Wolfe Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 601
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Baltimore
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21205
CY2022	dei	City Area Code CityAreaCode	(856)
CY2022	dei	Local Phone Number LocalPhoneNumber	848-8698
CY2022	dei	Security12b Title Security12bTitle	Shares of Common Stock, no par value
CY2022	dei	Trading Symbol TradingSymbol	MYMD
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	70298348	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39470009	shares
CY2022	dei	Auditor Firm AuditorFirmId	536
CY2022	dei	Auditor Name AuditorName	Morison Cogen LLP
CY2022	dei	Auditor Location AuditorLocation	Blue Bell, Pennsylvania
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	749090	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	555967	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4086902	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11003071	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	565787	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1106347	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5401779	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	12665385	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139662	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149009	usd
CY2022Q4	us-gaap	Goodwill Goodwill	10498539	usd
CY2021Q4	us-gaap	Goodwill Goodwill	10498539	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12138201	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12147548	usd
CY2022Q4	us-gaap	Assets Assets	17539980	usd
CY2021Q4	us-gaap	Assets Assets	24812933	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2673221	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	986626	usd
CY2022Q4	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	29982	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65780	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53240	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2768983	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1039866	usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent	29982	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75941	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95911	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	75941	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	125893	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2844924	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1165759	usd
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39470009	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39470009	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37673110	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37673110	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	108309436	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	102064218	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93758904	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78561568	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17539980	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24812933	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5520150	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6420092	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9067422	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6745104	usd
CY2021	MYMD	Accretion Of Debt Discount AccretionOfDebtDiscount	608460	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	695191	usd
CY2021	MYMD	Stock Option Modification Expenses StockOptionModificationExpenses	15036051	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15282763	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-28809707	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	83991	usd
CY2021	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	8907	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-5964	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	39597	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2958	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-42793	usd
CY2021	MYMD	Gain On Debt Forgiveness GainOnDebtForgiveness	180257	usd
CY2022	MYMD	Uninsured Casualty Losses UninsuredCasualtyLosses	4442	usd
CY2021	MYMD	Uninsured Casualty Losses UninsuredCasualtyLosses	-1265306	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	85427	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1079338	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15197336	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29889045	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15197336	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29889045	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38825763	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35017244	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15197336	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5550028	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	444342	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	165997	usd
CY2022	MYMD	Stock Issued During Period Value Compensation Of Warrants StockIssuedDuringPeriodValueCompensationOfWarrants	84851	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5257032	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5257032	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29889045	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	42477358	usd
CY2021Q2	MYMD	Exchange Ratio Price Per Shares ExchangeRatioPricePerShares	0.7718
CY2021	MYMD	Modification Of Pre Merger Stock Option Shares ModificationOfPreMergerStockOptionShares	4188315	shares
CY2021	MYMD	Modification Terms Of Pre Merger Stock Options ModificationTermsOfPreMergerStockOptions	15036051	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	90002	usd
CY2021	MYMD	Exercise Of Warrants For Common Stock ExerciseOfWarrantsForCommonStock	1189840	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15197336	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-29889045	usd
CY2021	MYMD	Accrued Interestdividends AccruedInterestdividends	-3024	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	608460	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-5964	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	39597	usd
CY2022	MYMD	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	-2958	usd
CY2021	MYMD	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	42793	usd
CY2021	MYMD	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt	180258	usd
CY2021	MYMD	Stock Option Modification Expenses StockOptionModificationExpenses	15036051	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	338922	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	105420	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	90002	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	84851	usd
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	165997	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-540560	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	912815	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1686595	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-4268961	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1917	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-81	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12270068	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19516475	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	4836837	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13403	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11750000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	18483176	usd
CY2021	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	1380852	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6913163	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19850625	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	3062444	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	120000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1826137	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5550028	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1189840	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5550028	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73533	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	193123	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	407683	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	555967	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148284	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	749090	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	555967	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	13322	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	271800	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	53196	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	141387	usd
CY2021	MYMD	Other Asset Investment OtherAssetInvestment	1500000	usd
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2 reverse stock split
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zitK6G4H5AMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b) <span id="xdx_861_zdVe4a17sanl">Use of Estimates and Judgments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for recording research and development expenses, impairment of intangible assets and the valuation of share-based payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-5964	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	39597	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11750000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	18483176	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	4836837	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13403	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zw5YAmiRVZPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(h) <span id="xdx_864_zpAtJtp7O5tk">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions and accounts receivable. At times, the Company’s cash in banks is in excess of the FDIC insurance limit. The Company has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P12M
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139662	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149009	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65780	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53240	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75941	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95911	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	77632	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	202226	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	75852	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P25Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	77005	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	74451	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5814	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	157270	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15549	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	141721	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13885695	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12630494	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	749090	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4086902	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15197336	usd
CY2022Q4	MYMD	Working Capital WorkingCapital	2632796	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93758904	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12270068	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15197336	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	695191	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1686595	usd
CY2022	MYMD	Decrease In Prepaid Expense DecreaseInPrepaidExpense	540560	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2356555	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	867518	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	316666	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	119108	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2673221	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	986626	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4176737	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.59
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.59
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M14D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14493284	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	300000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.41
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.41
CY2022	MYMD	Weighted Average Remaining Contractual Term Granted WeightedAverageRemainingContractualTermGranted	P5Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4476737	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.64
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y7M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4376737	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.61
CY2022	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	2.61
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y6M7D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	113847	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11576	shares
CY2021Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11576	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.59
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29982	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1411764	shares
CY2022Q3	us-gaap	Share Price SharePrice	4.25
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1411764	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1411764	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5999997	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	179000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26176000	usd
CY2022Q3	MYMD	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	5550028	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	93233	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.98
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.99
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5914000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6219000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5914000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-6219000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.145	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.090	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.041	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.093	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.389	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.208	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2018Q1	MYMD	Percentage Of Net Income For Each Subsequent Period PercentageOfNetIncomeForEachSubsequentPeriod	0.80	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3800000	usd
CY2022Q4	MYMD	Cumulative Change In Ownership Percentage CumulativeChangeInOwnershipPercentage	0.50	pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	745000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23526000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	2177000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	610000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	610000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4542000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4021000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34250000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28336000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5900000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-6200000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	41443	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	16514	usd

Files In Submission

Name	View Source	Status
0001493152-23-010384-index-headers.html	Edgar Link	pending
0001493152-23-010384-index.html	Edgar Link	pending
0001493152-23-010384.txt	Edgar Link	pending
0001493152-23-010384-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mymd-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
mymd-20221231_cal.xml	Edgar Link	unprocessable
mymd-20221231_def.xml	Edgar Link	unprocessable
mymd-20221231_lab.xml	Edgar Link	unprocessable
mymd-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

2023 Q1 Form 10-K Financial Statement

#000149315223010384 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA TNF Pharmaceuticals, Inc. Stock $tnfa

2023 Q1 Form 10-K Financial Statement

#000149315223010384 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa